STOCK TITAN

Praxis Precision Medicines Inc - PRAX STOCK NEWS

Welcome to our dedicated news page for Praxis Precision Medicines (Ticker: PRAX), a resource for investors and traders seeking the latest updates and insights on Praxis Precision Medicines.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Praxis Precision Medicines's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Praxis Precision Medicines's position in the market.

Rhea-AI Summary
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) announces the presentation of two abstracts at the American Academy of Neurology 2024 Annual Meeting showcasing progress in evaluating ulixacaltamide for essential tremor. The innovative Phase 3 clinical program sets a new standard for future trials in CNS disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.49%
Tags
conferences
-
Rhea-AI Summary
Praxis Precision Medicines, Inc. (PRAX) will participate in upcoming healthcare conferences in April, including the Needham 23rd Annual Healthcare Conference and the Piper Sandler Spring Biopharma Symposium. The company aims to showcase its genetic insights-driven therapies for CNS disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.72%
Tags
conferences
-
Rhea-AI Summary
Praxis Precision Medicines, Inc. granted non-qualified stock options and restricted stock units to a new non-executive employee under the 2024 Inducement Plan. The options have an exercise price of $58.60 per share and will vest over four years, while the restricted stock units will vest in four equal annual installments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.62%
Tags
none
Rhea-AI Summary
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) announced the pricing of its underwritten public offering, raising approximately $200 million. The offering includes 3,318,585 shares of common stock and pre-funded warrants. Praxis granted underwriters an option for additional shares, with the closing expected soon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.07%
Tags
-
Rhea-AI Summary
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) announced a proposed public offering of common stock and prefunded warrants to certain investors. The offering, managed by Piper Sandler, Guggenheim Securities, and Truist Securities, includes an option for underwriters to purchase additional shares. The offering is subject to market conditions and regulatory approvals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.07%
Tags
-
Rhea-AI Summary
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) reports positive results from Phase 2a study of PRAX-628 in epilepsy patients with PPR, showing high complete response rates in both 15mg and 45mg cohorts. Safety profile remains favorable, paving the way for an efficacy study in focal onset epilepsy in the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.13%
Tags
none
Rhea-AI Summary
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) will host a virtual program update to discuss its PRAX-628 program in epilepsy on March 26, 2024. The event will feature key opinion leader Dr. Daniel Friedman, Professor of Neurology at NYU Grossman School of Medicine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.13%
Tags
conferences
-
Rhea-AI Summary
Praxis Precision Medicines, Inc. reports strong progress in various clinical studies for CNS disorders, including essential tremor and epilepsy. They have received over 3,000 referrals for ulixacaltamide Phase 3 studies and expect topline results by 2024. The PRAX-628 study in epilepsy patients showed promising preliminary results. Additionally, the EMBRAVE study of elsunersen demonstrated a 43% median reduction in seizures and received PRIME designation from the EMA. Praxis also announced a licensing partnership with Tenacia Biotechnology for ulixacaltamide development in Greater China.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.88%
Tags
-
Rhea-AI Summary
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) will participate in the TD Cowen 44th Annual Health Care Conference in Boston from March 4 – 6, 2024. The company will engage in one-on-one investor meetings and a corporate panel discussion on orphan epilepsies. The webcast of the panel discussion will be available on the company's website for 90 days post-event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.9%
Tags
conferences
Rhea-AI Summary
Praxis Precision Medicines, Inc. (PRAX) granted non-qualified stock options and restricted stock units to new non-executive employees under the 2024 Inducement Plan. The options have an exercise price of $43.73 per share and will vest over four years, while the restricted stock units will vest in four equal annual installments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Praxis Precision Medicines Inc

Nasdaq:PRAX

PRAX Rankings

PRAX Stock Data

712.49M
11.01M
0.21%
60.89%
3.09%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Boston

About PRAX

praxis precision medicines, inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. its lead product candidates include prax-114, an extrasynaptic-preferring gabaa receptor positive allosteric modulator that is in phase iia clinical trial for the treatment of major depressive disorder and perimenopausal depression; and prax-944, a selective small molecule inhibitor of t-type calcium channels, which is in phase iia clinical trial for the treatment of essential tremor. the company is also developing prax-562, a persistent sodium current blocker that is in phase i clinical trial to treat severe pediatric epilepsy and adult cephalgia; prax-222, an antisense oligonucleotide for patients with gain-of-function (gof) scn2a epilepsy; and kcnt1 program for the treatment of kcnt1 gof epilepsy. it has a cooperation and license agreement with rogcon inc.; a license agreement purdue neuroscience company; and a res